NASDAQ: FEMYFemasys Inc Stock
$0.97-0.01 (-1.02%)
Updated Jun 30, 2025
FEMY Price
$0.97
Fair Value Price
N/A
Market Cap
$26.31M
52 Week Low
$0.69
52 Week High
$1.80
P/E
-1.06x
P/B
13.18x
P/S
18.5x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.70M
Earnings
-$21.11M
Gross Margin
66.2%
Operating Margin
-1,142.11%
Profit Margin
-1,242.6%
Debt to Equity
5.65
Operating Cash Flow
-$20M
Beta
0.55
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
FEMY Overview
Femasys Inc., a biomedical company, offers surgical and non-surgical infertility products (FemaSeed, FemCerv, FemEMB) and permanent birth control solutions (FemBloc, FemChec) in the U.S. and internationally. Femasys offers its products to obstetrics-gynecological physicians, women's healthcare provider organizations, and reproductive endocrinologists. Femasys was incorporated in 2004 and is based in Suwanee, GA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine FEMY's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical
Industry Rating
C
FEMY
Ranked#40 of 44
Ranked#40 of 44
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $6.24 | A | |
| $9.69 | B | |
| $93.48 | B |
Be the first to know about important FEMY news, forecast changes, insider trades & much more!
FEMY News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how FEMY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FEMY is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
FEMY is poor value based on its book value relative to its share price (13.18x), compared to the US Medical Instruments & Supplies industry average (3.7x)
P/B vs Industry Valuation
FEMY is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more FEMY due diligence checks available for Premium users.
Valuation
FEMY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.06x
Industry
41.77x
Market
32.47x
FEMY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
13.18x
Industry
3.7x
FEMY is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
FEMY's financial health
Profit margin
Revenue
$341.3k
Net Income
-$5.9M
Profit Margin
-1,727.9%
FEMY's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
FEMY's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$13.3M
Liabilities
$11.3M
Debt to equity
5.65
FEMY's short-term liabilities ($9.84M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FEMY's short-term assets ($9.13M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FEMY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.8M
Investing
-$96.6k
Financing
$5.2M
FEMY's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
FEMY vs Medical Stocks
Femasys Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.